Buprenorphine has potent kappa opioid receptor antagonist activity

Pharmacological characterization in vivo of the novel opiate, beta-funaltrexamine.

Ward, S. J., Portoghese, P. S., & Takemori, A. E. (1982) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32972-1 · Cited by 301

A kappa opioid effect: increased urination in the rat.

Leander, J. D. (1983) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33435-x · Cited by 225

Further study of kappa opioids on increased urination.

Leander, J. D. (1983) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22031-6 · Cited by 97

Evidence that nalorphine, butorphanol and oxilorphan are partial agonists at a κ-opioid receptor

Leander, J. D. (1983) · European Journal of Pharmacology · doi:10.1016/0014-2999(83)90198-x · Cited by 69

Further demonstration of kappa opioid binding sites in the brain: evidence for heterogeneity.

Su, T. (1985) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20058-1 · Cited by 63

Animal and molecular pharmacology of mixed agonist‐antagonist analgesic drugs.

Rance, M. J. (1979) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1979.tb04701.x · Cited by 58

Opioid agonist and antagonist behavioural effects of buprenorphine

Leander, J. D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb09410.x · Cited by 39

Compounds of novel structure having kappa-agonist behavioral effects in Rhesus monkeys

Katz, J. L., Woods, J. H., Winger, G. D., & Jacobson, A. E. (1982) · Life Sciences · doi:10.1016/0024-3205(82)90160-6 · Cited by 26

Voriconazole greatly increases the exposure to oral buprenorphine

Fihlman, M., Hemmilä, T., Hagelberg, N. M., Backman, J. T., Laitila, J., Laine, K., Neuvonen, P. J., Olkkola, K. T., & Saari, T. I. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2548-8 · Cited by 13

Locomotor and anti-immobility effects of buprenorphine in combination with the opioid receptor modulator samidorphan in rats

Burke, N. N., Ferdousi, M. I., Deaver, D. R., Finn, D. P., Roche, M., & Kelly, J. P. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.12.012 · Cited by 13

Opioidergic Agents as Antidepressants: Rationale and Promise

Saxena, P. P., & Bodkin, J. A. (2018) · CNS Drugs · doi:10.1007/s40263-018-0584-7 · Cited by 13

The effects of chronic morphine on the generalization of buprenorphine stimulus control: An assessment of kappa antagonist activity

Riley, A. L., & Pournaghash, S. (1995) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)00180-5 · Cited by 13

Going beyond efficacy: supportive care and addressing the toxicity of systemic therapy

Verma, S. (2008) · Current Oncology · doi:10.3747/co.2008.175 · Cited by 12

Buprenorphine-cocaine Interactions in Mice: Effect on Locomotor Activity and Hole-dipping Behaviour

Jackson, H. C., Griffin, I. J., & Nutt, D. (1993) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1993.tb05668.x · Cited by 12

Buprenorphine-Sustained Release Alters Hemodynamic Parameters in a Rat Burn Model

Guillory, A. N., Clayton, R. P., Prasai, A., Jay, J. W., Wetzel, M. D., Ayadi, A. E., Herndon, D. N., & Finnerty, C. C. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.03.016 · Cited by 11

An Opioid for Depression?

Kosten, T. R. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010078 · Cited by 10

A review of kappa opioid receptor antagonists and their clinical trial landscape

Lobe, M. M. M., Verma, S. K., Patil, V. M., & Iyer, M. R. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117205 · Cited by 9

Effects of intrathecal and intracerebroventricular buprenorphine on a C-fiber reflex in the rat.

Guirimand, F., CHAUVIN, M., Willer, J. C., & Bars, D. L. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12110-1 · Cited by 9

EU PNR: European Flight Passengers Under General Suspicion – The Envisaged European Model of Analyzing Flight Passenger Data

Boehm, F. (2011) · Springer eBooks · doi:10.1007/978-94-007-0641-5_8 · Cited by 6

Should Cocaine-Abusing, Buprenorphine-Maintained Patients Receive Auricular Acupuncture? Findings from an Acute Effects Study

Margolin, A., & Avants, S. K. (1999) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.1999.5.567 · Cited by 6

Sublingual buprenorphine/naloxone treatment is not affected by OPRM1 A118G and BDNF Va66Met polymorphisms, but alters the plasma beta-endorphin and BDNF levels in individuals with opioid use disorder

Kaya-Akyüzlü, D., Özkan-Kotiloğlu, S., Bal, C., Avcıoğlu, G., Şahiner, Ş. Y., & Şahiner, İ. V. (2022) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2022.103979 · Cited by 5

Multicenter Observational/Exploratory Study Addressed to the Evaluation of the Effectiveness and Safety of Pharmacological Therapy in Opioid-Dependent Patients in Maintenance Therapy in Southern Italy

Maqoud, F., Fabio, G., Ciliero, N., Antonacci, M., Mastrangelo, F., Sammarruco, G., Cataldini, R., Schirosi, G., Fazio, S. D., & Tricarico, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020461 · Cited by 5

OPRD1 rs569356 polymorphism has an effect on plasma norbuprenorphine levels and dose/kg-normalized norbuprenorphine values in individuals with opioid use disorder

Kaya-Akyüzlü, D., Özkan-Kotiloğlu, S., Danışman, M., Bal, C., Oğur, B., & İspir, G. Z. (2023) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2023.104143 · Cited by 5

Buprenorphine‐associated gastroparesis during in‐patient heroin detoxification

Jakobovits, S. L., Mcdonough, M., & Chen, R. Y. (2007) · Addiction · doi:10.1111/j.1360-0443.2006.01684.x · Cited by 5

Evaluating drug withdrawal syndrome risks through food and drug administration adverse event reporting system: a comprehensive disproportionality analysis

Zhang, Z., Yang, Q., Chen, M., Yang, W., & Wang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1385651 · Cited by 4

Buprenorphine reduces somatic withdrawal in a mouse model of early-life morphine exposure

Lepore, G. R., Morley-McLaughlin, T., Davidson, N., Han, C., Masese, C., Reynolds, G. F., Saltz, V., & Robinson, S. A. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109938 · Cited by 4

Opiate Receptors: Opioid Agonist‐Antagonist Effects

GOLDSTEIN, D. J., & Meador‐Woodruff, J. H. (1991) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1991.tb02613.x · Cited by 4

Synthesis of high specific activity [15,16‐3H2]buprenorphine

Ötvös, F., Hosztafi, S., Simon, C., & Tóth, G. (1995) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.2580360110 · Cited by 4

Going Beyond Efficacy: Strategies for Cancer Pain Management

Myers, J., & Shetty, N. (2008) · Current Oncology · doi:10.3747/co.v15i0.201 · Cited by 4

When does bulk interception of communications violate the right to privacy? The limits of the state’s power and the European Court of Human Rights Approach

Турањанин, В. (2022) · International Cybersecurity Law Review · doi:10.1365/s43439-022-00074-7 · Cited by 3

Medicines and the drug control treaties: is buprenorphine for opioid addiction at risk of being lost?

Silva, J. A. C. E. (2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.588 · Cited by 3

Good Governance, Rights and State: Quo Vadis Administrative Law?

Kaplan, O. (2022) · Uluslararası Yönetim Akademisi Dergisi · doi:10.33712/mana.1174475 · Cited by 2

Pharmacological Diversity in Opioid Analgesics: Lessons From Clinically Useful Drugs

Acevedo‐Canabal, A., Pantouli, F., Ravichandran, A., Rullo, L., & Bohn, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00188-2 · Cited by 2

Association of PDYN 68-bp VNTR polymorphism with sublingual buprenorphine/naloxone treatment and with opioid or alcohol use disorder: Effect on craving, depression, anxiety and age onset of first use

Kaya-Akyüzlü, D., Özkan-Kotiloğlu, S., Şahiner, Ş. Y., ERTAN, E. A., & İlhan, İ. Ö. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174862 · Cited by 2

Dijital Çağda Mahremiyetin Sınırları: Özel Hayatın Gizliliği Hakkı ve Elektronik Gözetim

Çatal, B. (2025) · Sakarya Üniversitesi Hukuk Fakültesi Dergisi · doi:10.56701/shd.1719579 · Cited by 1

Survey on the use of buprenorphine patches in the palliative care practice

Bourne, F. M., & Żylicz, Z. (2010) · Advances in Palliative Medicine · Cited by 1

A single injection of high-concentration buprenorphine significantly reduces food and water intake as well as fecal and urine production in New Zealand White rabbits (Oryctolagus cuniculus)

Gronsky, S., Girolamo, N. D., Maranville, R., Pathak, D., Womble, W., Hanzlicek, A. S., Sypniewski, L. A., & Brandão, J. (2024) · American Journal of Veterinary Research · doi:10.2460/ajvr.23.10.0230 · Cited by 1

TOPLUMUN ve BİREYİN BİLGİ EDİNME HAKKI

Zorlu, E. S. (2021) · Tekirdağ Namık Kemal Üniversitesi Hukuk Fakültesi Dergisi · doi:10.51562/nkuhukuk.2021227 · Cited by 1

Article 10 of the European Convention on Human Rights and the Public’s Right to Information Regarding Sports Events

Lefever, K. (2012) · ASSER international sports law series · doi:10.1007/978-90-6704-873-6_4

Buprenorfina w plastrach. Szereg odpowiedzi na dręczące pytania

Żylicz, Z. (2012) · Via Medica Journals

Methadone and Buprenorphine Prescribing in the Palliative Care Population

Dalal, S., & Bruera, E. D. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6974-2_17

Zentral wirksame Analgetika vom Typ Opioid

Waldvogel, H. H. (2001) · Springer eBooks · doi:10.1007/978-3-642-56710-0_37

Office-based buprenorphine to wean patients off opioids

Murinova, N., Krashin, D. L., Gevirtz, C., & Kaye, A. D. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107281950.064

Biochemical, functional and pharmacological characterization of novel bifunctional peptide ligands and nociceptin variants

Erdei, A. (2019) · doi:10.14232/phd.10243

Special Topics

Kaye, A. D., & Shah, R. V. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107281950.053

Faculty Opinions recommendation of Mu opioids and their receptors: evolution of a concept.

Davis, M. (2014) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718242989.793489851

Faculty Opinions recommendation of Attenuation of antidepressant effects of ketamine by opioid receptor antagonism.

Hen, R. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733878336.793552589

IMPACT OF BUPRENORPHINE THERAPY ON THE NORMALIZATION OF SEXUAL FUNCTION AND STATES OF ANXIETY

Trajanovska, A. S., & Pereska, Z. (2025) · MEDIS – International Journal of Medical Sciences and Research · doi:10.35120/medisij040249s

La sécurité nationale et le droit international

Zourabichvili, A. (2019) · doi:10.70675/4be172f1z9444z44e9z9b0azc3b22ee6c56e

Kappa antagonist properties of buprenorphine in non-tolerant and morphine-tolerant rats

Negus, S. S., Picker, M. J., & Dykstra, L. (1989) · Psychopharmacology · doi:10.1007/bf00442021 · Cited by 58

Buprenorphine is a potent κ-opioid receptor antagonist in pigeons and mice

Leander, J. D. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90543-2 · Cited by 104

Buprenorphine is an Antagonist at the ϰ Opioid Receptor

Richards, M. L., & Sadée, W. (1985) · Pharmaceutical Research · doi:10.1023/a:1016340106299 · Cited by 37

Antagonism of bremazocine‐induced urination as a test for kappa‐opioid receptor antagonists within the phenylpiperidine series

David, L. J., & Zimmerman, D. M. (1984) · Drug Development Research · doi:10.1002/ddr.430040405 · Cited by 5

Agonist and Antagonist Actions of Buprenorphine on Three Types of Opioid Receptor in Isolated Preparations

Kajiwara, M., Aoki, K., ISHII, K., Numata, H., Matsumiya, T., & Oka, T. (1986) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.40.95 · Cited by 40